ASCO 2019 /
NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer?

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

The information in this video was of interest to me Disagree Agree
The information in this video is likely to improve my clinical practice or research Disagree Agree
I would recommend this video to my colleagues Disagree Agree

Submit

Thanks for rating

There has been a problem, please refresh and try again.

Published: 13.06.19

Rating:

Shortlist Rate Video Transcript

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Prof Matthew Galsky talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the NILE trial.

He give a brief overview of the trial, and explains how it could define the new standard of care in this setting.

Prostate & urology · Biology · Control, survivorships & outcomes · Detection, diagnosis & prognosis · Antibodies & immunotherapy · Cytotoxics · ASCO 2019